MedPath

KAEL-GemVax Co., Ltd.

πŸ‡°πŸ‡·South Korea
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.kaelgemvax.com

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer

Phase 3
Conditions
Inoperable Stage III Non-small Cell Lung Cancer
Interventions
Drug: normal saline
First Posted Date
2012-04-17
Last Posted Date
2012-04-19
Lead Sponsor
Kael-GemVax Co., Ltd.
Target Recruit Count
600
Registration Number
NCT01579188

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

Phase 2
Conditions
Prostate Cancer
First Posted Date
2007-08-09
Last Posted Date
2012-08-09
Lead Sponsor
Kael-GemVax Co., Ltd.
Target Recruit Count
54
Registration Number
NCT00514072
Locations
πŸ‡ΊπŸ‡Έ

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.